UBS Maintains a Buy on Genmab (GMAB) With a DKK2,500 PT

UBS Maintains a Buy on Genmab (GMAB) With a DKK2,500 PT

Upworthy

Published

In This Article: Genmab A/S (NASDAQ:GMAB) is one of the 13 Cheap Healthcare Stocks with Huge Upside Potential. On June 25, UBS analyst Xian Deng maintained a Buy rating on Genmab A/S (NASDAQ:GMAB) and set a price target of DKK2,500.00. A scientist in a lab using a microscope to develop new…

Full Article